Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
280
-
Total 13F shares, excl. options
-
78.3M
-
Shares change
-
+629K
-
Total reported value, excl. options
-
$2.91B
-
Value change
-
+$28.2M
-
Put/Call ratio
-
0.8
-
Number of buys
-
134
-
Number of sells
-
-125
-
Price
-
$37.27
Significant Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q1 2023
340 filings reported holding NTLA - Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2023.
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) has 280 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78.3M shares
of 108M outstanding shares and own 72.6% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (9.84M shares), VANGUARD GROUP INC (8.13M shares), BlackRock Inc. (7.35M shares), STATE STREET CORP (3.54M shares), Nikko Asset Management Americas, Inc. (3.11M shares), Sumitomo Mitsui Trust Holdings, Inc. (3.11M shares), WELLINGTON MANAGEMENT GROUP LLP (2.97M shares), MORGAN STANLEY (2.66M shares), FEDERATED HERMES, INC. (2.02M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.87M shares).
This table shows the top 280 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.